Prolias Technologies Inc.
Prolias Technologies Inc. is an emerging molecular diagnostics company focusing on predictive and prognostic genetic cytology. Their molecular tests, THYMIRA™ and ARMIRA™ provide a definitive pathological diagnosis that allows for more accurate utility of surgical procedures. Prolias's miRNA biomarker technology allows physicians to more accurately manage indeterminate results obtained with Fine Needle Aspiration (FNA) samples from Thyroid nodules. The miRNA technology used in ARMIRA™ allows physicians to track kidney transplant rejection and renal allograft function. The company is committed to patient care through discovery and commercialization of molecular tests across a range of disease states and medical specialties.
The company's foundational technology was developed at Weill Cornell Medicine.